Related Experiment Video
Updated: May 26, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
The prevalence of viral hepatitis C in Latvia: a population-based study
Ieva Tolmane1, Baiba Rozentale, Jazeps Keiss
1Hepatology Department, State Agency, Infectology Center of Latvia, Riga, Latvia. ieva.tolmane@inbox.lv
Insights
Prevalence of antibodies to hepatitis C virus (anti-HCV) in Latvia was 2.4%, and hepatitis C virus RNA (HCV-RNA) prevalence was 1.7%. Both anti-HCV and HCV-RNA were more common in men than women.
Area of Science:
- Epidemiology
- Infectious Diseases
- Virology
Background:
- Chronic viral hepatitis C (VHC) affects approximately 170 million people globally, with over 9 million in Europe.
- Understanding the prevalence of VHC in specific regions is crucial for public health strategies.
Purpose of the Study:
- To determine the prevalence of antibodies to hepatitis C virus (anti-HCV) in Latvia.
- To ascertain the prevalence of active hepatitis C virus RNA (HCV-RNA) viremia in Latvia.
Main Methods:
- A multistage randomized selection of 42 primary care physicians (PCPs) across Latvia.
- 1651 individuals were invited for anti-HCV screening via ELISA, with positive results confirmed by Western blot.
- HCV-RNA testing using polymerase chain reaction was performed on individuals with confirmed anti-HCV antibodies.
Main Results:
- Out of 1459 tested subjects, 3.9% were initially positive for anti-HCV, with a confirmed prevalence of 2.4%.
- HCV-RNA prevalence was found to be 1.7% among the tested population.
- Both anti-HCV (3.8% vs 1.7%) and HCV-RNA (3% vs 1%) prevalence were significantly higher in men compared to women.
Conclusions:
- The confirmed prevalence of anti-HCV in Latvia is 2.4%, and HCV-RNA prevalence is 1.7%.
- Hepatitis C virus infection shows a higher prevalence in men than in women in Latvia.
Background And Objective:
Chronic viral hepatitis C (VHC) is one of the most discussed infectious diseases worldwide. The number of infected persons worldwide is approximately 170 million, and in Europe, it exceeds 9 million. The aim of this study was to determine the prevalence of antibodies to hepatitis C virus (anti-HCV prevalence) and prevalence of HCV viremia (HCV-RNA prevalence) in Latvia.
Material And Methods:
A multistage randomized selection was used. A total of 42 primary care physicians (PCPs) were randomly selected from the register of PCPs from different regions of Latvia. From each PCP register, 60 subjects were selected (1651 individuals in total) and invited for the anti-HCV test with a screening method (ELISA). In case of positive results, antibodies were confirmed by the Western blot test, and all these subjects were tested for HCV-RNA by polymerase chain reaction.
Results:
Of the 1459 subjects tested, 57 were positive for anti-HCV (3.9%; 95% CI 3% to 5%); 35 of them were positive for anti-HCV with a confirmatory test (2.4%; 95% CI, 1.7% to 3.3%): 19 men and 16 women (3.8% and 1.7%, respectively; P=0.011). The results of HCV RNA test were positive in 25 subjects (1.7%; 95% CI, 1.2% to 2.5%): 15 men and 10 women (3% and 1% respectively, P=0.019).
Conclusions:
The prevalence of anti-HCV and HCV-RNA in Latvia was found to be 2.4% and 1.7%, respectively. The prevalence of anti-HCV and HCV-RNA was higher in men than women.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Cytomegalovirus Disease
Retrovirus Life Cycles
Human Virome

